FDA Authorized Modified-Risk Claims for ZYN Pouches
The agency approved modified-risk claims for 20 ZYN products, allowing labels to note lower disease risk than cigarettes.
Updated on Oct. 9, 2026 in Nutrition
Live Poll
Should the FDA allow nicotine product manufacturers to advertise lower-risk health claims?
In June 2026, the US FDA issued modified-risk orders for 20 ZYN nicotine pouch products manufactured by Swedish Match USA. The authorization permits the products to carry claims indicating they lower the risk of specific smoking-related diseases compared to cigarettes.
Why it matters
The agency aims to provide adult users with science-based information regarding relative tobacco harms, enabling more informed health choices. The decision marks the first time the FDA has issued such orders for nicotine pouches, balancing adult access with population-level health concerns.
The FDA authorized 20 nicotine pouch products for modified-risk claims based on a five-year validity period. These authorizations follow the initial marketing approval granted in January 2025.
The players
US FDA
The United States Food and Drug Administration is the federal agency responsible for regulating tobacco products and protecting public health.
Swedish Match USA
Swedish Match USA is the manufacturer of ZYN nicotine pouch products and a subsidiary of Philip Morris International.
The details
The FDA approved these claims after reviewing evidence concerning relative risks, consumer understanding, and the potential impact on public health. The agency retains the authority to withdraw these orders if mandatory market monitoring reveals an increase in youth usage.
Timeline
January 2025: ZYN products received initial marketing authorization from the US FDA.
June 30, 2026: The FDA officially issued the Modified Risk Tobacco Product orders.
October 9, 2026: News regarding the authorization was reported.
Health Landscape
This decision marks a shift in federal tobacco regulation by extending modified-risk designations to non-combustible nicotine delivery systems. The move underscores the agency's strategy of applying the regulatory framework of the Family Smoking Prevention and Tobacco Control Act to modern nicotine products.
Adult nicotine users will begin to see new labeling on ZYN products that highlights the potential for lower disease risk compared to traditional cigarettes. Consumers should be aware that these claims are subject to five years of federal monitoring to ensure they do not encourage youth nicotine use.
The takeaway
The FDA's authorization provides specific information for adult smokers looking to transition away from combustible cigarettes. Users should keep in mind that these products remain regulated nicotine delivery systems subject to ongoing federal oversight.
Further reading
For broader context on current federal guidelines, explore the Nutrition section.
Source note: This article includes information reported by Sun.Star Network Online.
Live Poll
Should the FDA allow nicotine product manufacturers to advertise lower-risk health claims?
